JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on KALV stock, giving a Buy rating today.
Debanjana Chatterjee has given his Buy rating due to a combination of factors surrounding KalVista Pharmaceuticals’ recent strategic moves and market potential. The company has entered into a licensing agreement with Kaken Pharmaceutical, allowing them to commercialize sebetralstat in Japan. This deal includes an upfront payment of $11 million and the potential for an additional $11 million upon reaching a regulatory milestone, along with commercial milestones and royalties in the mid-20% range on net annual sales.
Sebetralstat is poised to become the first oral on-demand therapy for hereditary angioedema (HAE) in Japan, with a launch expected in the first half of 2026. The upcoming PDUFA date in June 2025 for US approval is also a significant factor, with a high likelihood of approval. The potential for sebetralstat to capture a substantial market share as the first of its kind further supports the Buy rating.
In another report released today, Needham also maintained a Buy rating on the stock with a $28.00 price target.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KALV in relation to earlier this year.